• Product NameQuizartinib (AC220)
• Brief DescriptionInhibitors
• Purification99.42%
• Biological ActivityQuizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Phase 3.
• Target NameFLT inhibitor
• CAS No. 950769-58-1
• Calculated MW 560.67
• Formulation C29H32N6O4S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=C3C=CC(OCCN3CCOCC3)=C4)=N2)=NO1
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:FLT3 (ITD); FLT3 (WT)
  Boling pt:
  Melting pt:
  Solubility:DMSO: 33.2 mg/mL (59.21 mM)
  Appearance:Yellow Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Zarrinkar PP, et al. Blood, 2009, 114(14), 2984-2992.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting